Company
NuLynx
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
is developing first-in-field oncology therapeutics including orally bioavailable degraders and inhibitors targeting CDK12/13, PIKfyve, NSD2/1, and UBA1.
Loading relationship preview